Drug Trial Radar · NCT04421885
Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects
Last checked: Nov 19, 2026Latest source record: Aug 12, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Jun 1, 2020
Primary completion
Jul 11, 2020
Study completion Jul 29, 2020
Sponsor
- Lead sponsor
- Spero TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A bioequivalence and food-effect study comparing two tablet formulations of tebipenem pivoxil hydrobromide (TBPM-PI-HBr) in healthy adult subjects.
Conditions
- Healthy Volunteers
Interventions
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - ReferenceDrug
600 mg (2 x 300 mg tablets) clinical study drug product batch TBPM-PI-HBr.
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - TestDrug
600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the curve extrapolated to infinity (AUC0-∞).Time frame: 24h (Day 2) post dose (Arms: A, B, C)
- Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (t) (AUC0-t).Time frame: 24h (Day 2) post dose (Arms: A, B, C)
- Maximum plasma concentration (Cmax).Time frame: 24h (Day 2) post dose (Arms: A, B, C)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical Facility
Tempe, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.